Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-09
2011-08-09
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S123000, C564S161000, C564S183000, C514S613000
Reexamination Certificate
active
07994221
ABSTRACT:
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
REFERENCES:
patent: 5182303 (1993-01-01), Daub et al.
patent: 5194084 (1993-03-01), Findeisen et al.
patent: 5274098 (1993-12-01), Werner
patent: 5625073 (1997-04-01), Lindig et al.
patent: 5869681 (1999-02-01), Muller et al.
patent: 5904857 (1999-05-01), Bailey et al.
patent: 6524567 (2003-02-01), Laub
patent: 7687641 (2010-03-01), Jordan et al.
patent: 2003/0186842 (2003-10-01), Fitz et al.
patent: 2004/0054005 (2004-03-01), Lan et al.
patent: 2004/0063765 (2004-04-01), Ammendola et al.
patent: 2004/0077607 (2004-04-01), Uckun
patent: 2007/0254934 (2007-11-01), Hruby et al.
patent: 2007/0287735 (2007-12-01), Jordan et al.
patent: 2008/0004452 (2008-01-01), Jordan et al.
patent: 2008/0103181 (2008-05-01), Jordan et al.
patent: 2008/0300265 (2008-12-01), Hruby et al.
patent: 2009/0036513 (2009-02-01), Hruby et al.
patent: 2009/0180980 (2009-07-01), Hruby et al.
patent: 2009/0203675 (2009-08-01), Deng et al.
patent: 0283876 (1988-09-01), None
patent: 0294666 (1988-12-01), None
patent: 0398096 (1990-11-01), None
patent: WO9533719 (1995-12-01), None
patent: WO9920272 (1999-04-01), None
patent: 9933790 (1999-07-01), None
patent: WO2004096197 (2004-11-01), None
patent: WO 2004/112718 (2004-12-01), None
patent: WO 2005037257 (2005-04-01), None
patent: 2006062898 (2006-06-01), None
patent: WO 2006/062898 (2006-06-01), None
patent: WO03062265 (2007-07-01), None
patent: WO 2007/103111 (2007-09-01), None
patent: WO 2007/120374 (2007-10-01), None
patent: WO 2008079159 (2008-07-01), None
patent: WO 2007/100888 (2008-09-01), None
patent: WO 2008130348 (2008-10-01), None
patent: WO 2008/147962 (2008-12-01), None
patent: WO 2008147474 (2008-12-01), None
patent: 2009029622 (2009-03-01), None
patent: WO 2009/029622 (2009-03-01), None
patent: 2009123776 (2009-10-01), None
patent: WO 2009/123776 (2009-10-01), None
patent: WO 2009149054 (2009-12-01), None
Borio et al. Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management, JAMA, 2002, vol. 287 (18) 2391-2405.
Popov A.U. et al.: “Synthesis of 1,1-bis-(trifluoromethyl)alkylisocyanates, carbamates, and areas” Russian Chemical Bulletin, 2000, pp. 1202-1206.
Bolken T C et al: “Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses” Antiviral Research, Elsevier BV, NL, vol. 69,No. 2, Feb. 1, 2006, pp. 86-97.
Patani A et al: Bioisosterism: A Rational Approach in Drug Design Chemical Reviews, ACS, Washington, DC, US, vol. 96, No. 8, Jan. 1, 1996, pp. 3147-3176.
Co-pending U.S. Appl. No. 12/673,983, filed Feb. 18, 2010, Dai et al.
Office Action Dated Feb. 19, 2010, U.S. Appl. No. 11/712,918, filed Mar. 2, 2007, Inventor Hruby et al.
Office Action Dated Sep. 14, 2009, U.S. Appl. No. 10/561,153, filed Apr. 6, 2006, Inventor Jordan et al.
Office Action Dated May 6, 2009, U.S. Appl. No. 11/785,997, filed Apr. 23, 2007, Inventor Jordan et al.
Supplementary European Search Report EP Application No. 07751990.8, Dated Mar. 18, 2010.
Bagai, S. and Lamb, R. A., J. Cell Biol., 135: 73-84 (1996).
Beyer, W. R., et al., “Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range.” J. Virol. 76:1488-1495 (2002).
Beyer, W. R., et al., J. Virol., 77: 2866-72 (2003).
Bowen, M. D., et al., Virology, 219: 285-90 (1996).
Buchmeier, M.J., Clegg, J.C.S., Franze-Fernandez, M. T., Kolakofsky, D., Peters, C. J., and Southern, P. J., “Virus Taxonomy: Sixth Report of the International Committee on Taxonomy of Viruses,” Murphy, F.A., Fauquet, C. M. et al., Eds. Sprnger-Verlag, New York, 319-323 (1995).
Candurra, N. A., Maskin, L., and Pamonte, E.B., Inhibition of arenavirus multiplication in vitro byphenotiazines, Antiviral Res., 31(3): 149-158 (1996).
Castagna, A., et al., Drugs, 65: 879-904 (2005).
Charrel, R. N. and de Lamballerie X., Antiviral Research. 57:89-100 (2003).
Childs, J. E., and Peters, C. J., “The Arenaviridae” Ed Salvato (ed.), Plenum Press, New York, pp. 331-384 (1993).
Cianci, C., et al., Antimicrob Agents Chemother, 48: 2448-54 (2004).
Clegg, J. C., Curr Top Microbiol Immunol, 262: 1-24 (2002).
Clegg, J.C.S., Bowen, M.D., et al., “Arenavirideal” in Van Regenmortel, M. H. V., Fauquet, C. M.,Bishop, D. H. L., Carsten, E.B., Estes, M.K., Lemon, S.M., Maniloff, J., Mayo, M.A., McGeoch, D.J., Pringle, C.R., Wickner, R. B. (Eds) Virus Taxonomy. Seven Report of the International Committee for the Taxonomy of Viruses, Academic Press, New York, pp. 633-640 (2000).
Connor, R. I., et al., “Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.” Virology 206:935-944 (1995).
Enria, D. A., Feuillade, M. R., Levis, S., Briggiler, A. M., Ambrosio, A. M., Saavedra, M. C, Becker, J. L., Aviles, G., Garcia, J., Sabattini, M., “Impact of vaccination of a high-risk population for Argentine hemorrhagic fever with a live-attenuated Junin virus vaccine” in Saluzzo, J. F., Dodet, B., (eds) Factors in the Emergence and Control for Rodent-Borne Viral Diseases, Paris: Elsevier, 1999, pp. 273-276.
Enria, D.A., and Maiztegui, J.I., Antiviral treatment of Argentine Hemorrhagic Fever, Antiviral Res., 23: 23-31 (1994).
Froeschke, M., et al., J. Biol Chem., 278: 41914-20 (2003).
Garcia, C. C., et al., Antivir Chem Chemother, 11: 231-7 (2000).
Glushakova, S. E., Lakuba, A. I., Vasiuchkov, A.P., Mar'iankova, R. F., Kukareko, T. M., Stel'makh, T.A., Kurash, T. P., and Lukashevich, I. S., Lysosomotropic agents inhibit the penetration of arenavirus into a culture of BHK-21 andvero cells, Voprosy Virusolog II. 35(2): 146-150 (1990).
Hall, W. C., et al., Am J Trop Med Hyg, 55: 81-8 (1996).
Harman, A., et al., J Virol, 76: 10708-16 (2002).
Huggins, J.W., Prospects for Treatment of Viral Hemorrhagic Fevers With Ribavirin, A Broad-Spectrum Antiviral Drug, Rev. Infect. Dis., II:Suppl.4:S750-S761 (1989).
Jeetendra, E., et al., J Virol, 77: 12807-18 (2003).
Kilgore, P. E., Ksiazek, T. G., Rollin, P. E., et al., Treatment of Bolivian Hemorrhagic Fever with intravenous ribavirin, Clin. Infect. PIS., 24: 718-722 (1997).
Kinomoto, M., et al., J Virol, 79: 5996-6004 (2005).
Kunz, S., et al., Virology, 314: 168-78 (2003).
Leifer, E., Gocke, D.J., et al., Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease, Am. J. Trop. Med. Hyg., 19:677-679 (1970).
Lenz, O., et al., Proc Natl Acad Sci USA, 98: 12701-5 (2001).
Maron, M. D. and Ames, B. N., Mutat Res, 113: 173-215 (1983).
McCormick, J. B., Epidemiology and control of Lassa fever, Curr. Top. Microbiol. Immunol., 134: 69-78 (1987).
McCormick, J.B., King, I.J., Webb, P.A., et al., Lassa Fever: Effective therapy with Ribavirin, N. Engl. J. Med., 314: 20-26 (1986).
Naldini, L., et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.” Science 272:263-267 (1996).
Oldfield, V., et al., Drugs, 65: 1139-60 (2005).
Peters C. J., “Arenavirus diseases,” in Porterfield J., ed., Exotic Viral Infection, London: Chapman and Hall Medical, 227-246 (1995).
Peters, C. J., et al., Curr Top Microbiol Immunol, 134: 5-68 (1987).
Raw
Bailey Thomas R.
Bolken Tové C.
Dai Dongcheng
Hruby Dennis E.
Kramer Levin Naftalis & Frankel LLP
Shameem Golam M
Siga Technologies, Inc.
LandOfFree
Sulfonyl semicarbazides, carbonyl semicarbazides,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonyl semicarbazides, carbonyl semicarbazides,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonyl semicarbazides, carbonyl semicarbazides,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766103